FIELD: pharmaceutics.
SUBSTANCE: present invention relates to pharmaceutical preparations. In a specific embodiment, the solid dispersion contains an active ingredient (R)-4-amino-1-(1-(but-2-ynyl)pyrrolidin-3-yl))-3-(4-(2,6-difluorophenoxy)phenyl)-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one or a salt thereof, and a carrier material, and the pH value is adjustable; application of method, according to which a corresponding amount of acid is added, which effectively inhibits the emulsification phenomenon in the process with a reverse solvent, thus obtaining a solid dispersion having an average particle size and uniform content.
EFFECT: disclosed is a solid dispersion and a method for production thereof.
6 cl, 2 dwg, 3 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PREPARATION | 2018 |
|
RU2767872C2 |
| PHARMACEUTICAL COMPOSITION OF PYRAZOLE COMPOUND DISPERSED IN POLYMER MATRIX | 2020 |
|
RU2826604C1 |
| COMPOSITIONS OF SOLID DOSAGE FORMS OF OREXIN RECEPTOR ANTAGONIST | 2013 |
|
RU2759837C2 |
| ORAL SOLID PREPARATION OF COMPOUND ANTITUBERCULOSIS DRUG AND PREPARATION METHOD THEREOF | 2012 |
|
RU2605388C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2589842C2 |
| COMPOSITIONS OF SOLID DOSAGE FORMS OF AN OREXIN RECEPTOR ANTAGONIST | 2013 |
|
RU2699358C2 |
| TMC 125 PREPARATION SPRAY DRYING PRODUCTION PROCESS | 2007 |
|
RU2406502C2 |
| COMPOSITION OF THE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | 2014 |
|
RU2661399C1 |
| SUBSTITUTED PYRROLO [2,3-D] PYRIDAZIN-4-ONES AND PYRAZOLO [3,4-D] PYRIDAZIN-4-ONES AS PROTEINKINASE INHIBITORS | 2017 |
|
RU2749038C2 |
| SOLID DISPERSIONS | 2016 |
|
RU2694832C2 |
